In conclusion, our meta-analysis suggests a role BCL-2 promoter polymorphisms in cancer susceptibility and prognosis, rs2279115 but not rs1801018 may be a tumor marker for cancer therapy in Asia. The gene discussed is BCL2; the disease is neoplasm.